Bone Biologics (BBLGW) Non Operating Interest Expenses (2014 - 2025)

Bone Biologics (BBLGW) has reported Non Operating Interest Expenses for 10 consecutive years, with $88334.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non Operating Interest Expenses rose 1.61% year-over-year to $88334.0 in Q4 2025; TTM through Dec 2025 was $708398.0, a 5.41% increase from a year earlier, with the FY2025 full-year figure at $983054.0, up 6.04% from the prior year.
• Non Operating Interest Expenses was $88334.0 for Q4 2025 at Bone Biologics, down from $242297.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $290836.0 in Q3 2024 and troughed at $14755.0 in Q4 2021.
• A 3-year average of $189188.4 and a median of $246560.0 in 2021 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 12.6% in 2021, down 94.03% in 2021.
• Over 3 years, Non Operating Interest Expenses stood at $14755.0 in 2021, then surged by 489.16% to $86931.0 in 2024, then increased by 1.61% to $88334.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $88334.0 (Q4 2025), $242297.0 (Q3 2025), and $86931.0 (Q4 2024), per Business Quant data.